Results 101 to 110 of about 1,213,487 (359)

Weekly versus three weeks chemotherapy for advanced ovarian cancer. A meta-analysis [PDF]

, 2016
Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear.
De Felice, Francesca, Marchetti, Claudia, Monti, Marco, Musella, Angela, Musio, Daniela, Muzii, Ludovico, Palaia, Innocenza, Panici, Pierluigi Benedetti, Tombolini, Vincenzo   +8 more
core   +1 more source

Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal‐like and malignant urothelial cells

Molecular Oncology, EarlyView.
Loss of the frequently mutated chromatin remodeler ARID1A, a subunit of the SWI/SNF cBAF complex, results in less open chromatin, alternative splicing, and the failure to stop cells from progressing through the cell cycle after DNA damage in bladder (cancer) cells. Created in BioRender. Epigenetic regulators, such as the SWI/SNF complex, with important
Rebecca M. Schlösser, Florian Krumbach, Eyleen Corrales, Geoffroy Andrieux, Christian Preisinger, Franziska Liss, Alexandra Golzmann, Melanie Boerries, Kerstin Becker, Ruth Knüchel, Stefan Garczyk, Bernhard Lüscher   +11 more
wiley   +1 more source

Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer

OncoTargets and Therapy, 2014
Progression-free survival (PFS) and time to progression (TTP) are frequently used to establish the clinical efficacy of anti-cancer drugs. However, the surrogacy of PFS/TTP for overall survival (OS) remains a matter of uncertainty in metastatic breast cancer (mBC).
Dan Cooper, Louise Yelle, Jean Lachaine, Catherine Beauchemin, Marie Ève Lapierre   +4 more
openaire   +5 more sources

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

Molecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti, Manuel Scimeca, Julia Bischof, Jonathan Woodsmith, Massimiliano Agostini, Cristina Fiorani, Yufang Shi, Eleonora Candi, Gerry Melino, Alessandro Mauriello, Giuseppe S. Sica   +10 more
wiley   +1 more source

Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer

Journal of Cancer Research and Clinical Oncology, 2014
Purpose New treatment strategies, particularly the introduction of molecular-targeted agents and appropriate patient selection based on histology and/or genotyping, have progressed markedly in recent years, and the overall survival (OS) in advanced non ...
Masayuki Aboshi, Masayuki Kaneko, Mamoru Narukawa   +2 more
doaj   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan [Corrigendum]

Diabetes, Metabolic Syndrome and Obesity, 2021
Hisanaga K, Uchino H, Kakisu N, et al. Diabetes Metab Syndr Obes. 2021;14:773—781. Page 775, left column, third paragraph, line 4, the text “(p<0.5)” should read “(p<0.05)”.
Hisanaga K, Uchino H, Kakisu N, Miyagi M, Yoshikawa F, Sato G, Isobe K, Kishi K, Homma S, Hirose T   +9 more
doaj  

Feasibility and Efficacy of Definitive Radiotherapy with 66 Gy and Concurrent Carboplatin-Paclitaxel Chemotherapy for Stage III Non-Small Cell Lung Cancer. [PDF]

, 2017
Purpose/Objectives : This study was conducted to assess the feasibility and efficacy of definitive radiotherapy (RT) with a total dose of 66 Gy and concurrent carboplatin-paclitaxel chemotherapy for patients (pts) with stage Ⅲ non-small celllung cancer ...
Asakawa, Isao, Hasegawa, Masatoshi, Hontsu, Shigeto, Inoue, Kazuya, Kimura, Hiroshi, Miura, Sachiko, Tamamoto, Tetsuro, Yoshimine, Tadashi   +7 more
core  

A randomized trial of bevacizumab for newly diagnosed glioblastoma. [PDF]

, 2014
BACKGROUND: Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma.
Aldape, Kenneth D, Armstrong, Terri S, Blumenthal, Deborah T, Brachman, David G, Brown, Paul D, Chakravarti, Arnab, Colman, Howard, Curran, Walter J, Dignam, James J, Gilbert, Mark R, Jaeckle, Kurt A, Jeraj, Robert, Mehta, Minesh P, Pugh, Stephanie, Schiff, David, Stieber, Volker W, Sulman, Erik P, Tremont-Lukats, Ivo W, Vogelbaum, Michael A, Wefel, Jeffrey S, Werner-Wasik, Maria, Won, Minhee   +21 more
core   +2 more sources